PROGRAMME SCHEDULE (Tentative)
Time shown in IST (Indian Standard Time)
DAY-1: Thursday, 1st SEPTEMBER, 2022
|
1:00 to 1:05 PM 1:05 to 1:20 PM 1:20 to 1:30 PM |
Prayer by Chaplain Welcome and introductory remarks: Director, CMC / Principal, CMC / Director, inStem/ Head, CSCR Remarks by Secretary, Department of Biotechnology, Ministry of Science and Technology, Govt. of India |
|
|
Session-1: APPLICATIONS OF iPSC TECHNOLOGY |
||
| Indian Time | Title | Speaker Name |
|
1.30 to 2:00 PM |
Consistency and reliability of quality testing for induced Pluripotent Stem Cells
|
Stephen Sullivan |
| 2:00 to 2:30 PM | Assuring reproducibility: Sharing data on hPSC – lines and clinical trials |
Andreas Kurtz Charité-Universitäts medizin Berlin, Berlin, Germany |
| 2:30 to 3:00 PM | Creation of a Haplobank- Initiative in India |
Dolly Daniel Christian Medical college and Centre for Stem Cell Research, Vellore, India |
| 3:00 to 3:15 PM | Break | |
| 3:15 to 3:45 PM |
Poster presentation/ Industry Symposium |
|
|
Session-2: IMMUNE CELL THERAPY |
||
| Indian Time | Title | Speaker Name |
| 3:45 to 4:15 PM | CAR-T |
Hasmukh Jain Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India |
|
4:15 to 4:45 PM
|
Translation of CAR-T cells for cancer immunotherapy: from bench-to-bedside |
Anat Globerson Dana-Dwek Children’s Hospital, TelAviv, Israel |
|
4:45 to 5:15 PM |
CAR-T cell therapy for haematological malignancies or solid tumours |
Avery D. Posey University of Pennsylvania, Philadelphia, USA |
| 5:15 to 5:30PM | Break | |
|
Session-3: GENE THERAPY |
||
| Indian Time | Title | Speaker Name |
| 5:30 to 6:00 PM |
Nongenotoxic conditioning for transplant of genetically engineered HSCs: Is this the future for HSC-based gene therapy |
Trent Spencer Emory University School of Medicine, Atlanta, GA, USA |
| 6:00 to 6:30 PM | Gene Therapy for Platelet Derived Factor VIII Production in Hemophilia A |
David Wilcox Medical College of Wisconsin, US |
| 6:30 to 7:00 PM | lentiviral vector-based gene therapy for Haemophilia B |
Alok Srivastava Christian Medical college and Centre for Stem Cell Research, Vellore, India |
| KEY NOTE ADDRESS | ||
| 7:00 to 8:00 PM | TBC |
Luigi Naldini San Raffaele Telethon Institute for Gene Therapy, Milano, Italy |
| End of Day-1 | ||
DAY-2: Friday, 2nd SEPTEMBER, 2022
| Session-4: TECHNOLOGY ADVANCES | ||
| Indian Time | Title | Speaker Name |
| 2:00 to 2:30 PM | Assessing and mitigating off-target effects in therapeutic genome editing |
Toni Cathomen Institute of Transfusion Medicine and Gene Therapy, Germany |
| 2:30 to 3:00 PM | IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies |
Sebastien Lacroix-Desmazes Centre de Recherche des Cordeliers, France |
| 3:00 to 3:30 PM |
Base editors mediated gamma globin promoter screening |
Mohankumar Murugesan Centre for Stem Cell Research, Vellore, India |
| 3:30 to 4:00 PM |
Development of optimized (“Opt”) and generation Y (“GenY”) AAVrh74 vectors for gene therapy of muscular dystrophies |
Arun Srivastava University of Florida, Florida, USA |
| 4:00 to 4:15 PM | Break | |
|
Industry Symposium |
||
| Indian Time | Title | Speaker Name |
| 4:15 to 4:45 PM | TBD | |
| 4:45 to 5:15 PM |
TBD |
|
| 5:15 to 6:00 PM | Poster presentation | |
|
Session-6: MANUFACTURING AND REGULATORY ASPECTS IN CELL AND GENE THERAPY |
||
| Indian Time | Title | Speaker Name |
| 6:00 to 6:30 PM |
Manufacturing of Lentiviral vector for Haemophilia A
Lentiviral mediated genetic modification of HSC from Haemophilia A patients |
William Swaney Expression Manufacturing LLC, Georgia, USA Gurbind Singh Centre for Stem Cell Research, Vellore, India |
| 6:30 to 7:00 PM |
Advanced HSC clinical trials in the Necker hospital GMP facility |
Elisa Magrin and Jihene Benlagha Necker-Enfants Malades Hospital, Paris |
| 7:00 to 7:30 PM | Manufacturing of cellular product for clinical application |
Adrian Gee Baylor College of Medicine Houston, TX, US |
|
KEY NOTE ADDRESS |
||
| 7:30 to 8:30 PM | Evolution of lentiviral vector mediated gene modified autologous HSCs for the treatment of hemoglobin disorders |
Mark Walters UCSF Benioff Children’s Hospitals, California, USA |
|
End of Day-2 |
||
DAY-3: Saturday, 3rd SEPTEMBER, 2022
| Session-7: CELL AND GENE THERAPY- INDUSTRY UPDATES | |||
| Indian Time | Title | Speaker Name | |
| 2:00 to 2:30 PM | Future of Vaccinology-mRNA |
Ajay Singh Gennova Biopharma Ltd., Pune, India |
|
| 2:30 to 3:00 PM |
CAR-T cell Therapy-Bench to Bedside-the Immuneel approach |
Anil Kamat Immuneel Therapeutics Private Limited, Bangalore
|
|
| 3:00 to 3:30 PM | Allogeneic, Off the Shelf, Pooled, Bone marrow derived Mesenchymal Stromal Cells (Stempeucel®) – a Potential break through therapy for Grade II & III Osteoarthritis knee |
Pawan Kumar Gupta Stempeutics Research Pvt. Ltd., Bangalore |
|
| 3:30 to 3:45 PM |
Break |
||
| Session-8: GENE EDITING | |||
| India Time | Title | Speaker Name | |
| 3:45 to 4:15 PM |
A Mutation-Agnostic Hematopoietic Stem Cell Gene editing approach |
Justin Selvaraj University of Tübingen, Germany |
|
| 4:15 to 4:45 PM |
Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases |
Annarita Miccio Institute of genetic diseases Imagine, Paris Cite’ University, Paris, France |
|
| 4:45 to 5:15 PM | The CD34+CD90+HSCs as a target cell for CCR5 gene editing |
Saravanabhavan Thangavel Centre for Stem Cell Research, Vellore, India |
|
| 5:15 to 6:00 PM |
Poster presentation/ Industry Symposium |
||
|
Session-9: NON-VIRAL NUCLEIC ACID TRANSFER |
|||
| India Time | Title | Speaker Name | |
| 6:00 to 6:30 PM | Smart lipid nanoparticle enabled mRNA vaccine for SARS-CoV2 |
Srujan Marepally Centre for Stem Cell Research, Vellore, India |
|
|
6:30 to 7:00 PM |
Therapeutic applications of Cell penetrating siRNAs |
Oommen P. Oommen Tampere University and BioMediTech Institute, Finland |
|
|
7:00 to 7:30 PM |
Lipid nanoparticles T cell specific nucleic acid delivery in vivo |
Gaurav Saha Oregon State University, Oregon, US |
|
|
End of Day-3 |
|||